Work

High-Risk Mobility and Interruption in HIV Treatment Among Men in Malawi: Secondary Analysis of Two Randomized Controlled Trials

Year: 2026
Type: article
Abstract: Mobility is a key risk factor for interruption in HIV treatment (IIT). However, little is known about which aspects of mobility confer greatest risk (i.e., comprise high-risk mobility) and whether people prone to high-risk mobility can be identified prior to events. We conducted a secondary analysis of the IDEaL and ENGAGE trials (ClinicalTrials.gov #NCT04858243; #NCT05137210), which tested interventions to improve 6-month ART engagement among men living with HIV (MLHIV; ≥ 15 years old) not in care (i.e., ART naïve or missed refill by ≥ 28 days) in Malawi. We used baseline and endline (4–7 months post-enrollment) surveys and medical chart reviews of established ART clients experiencing IIT at enrollment who re-initiated ART during trials. We used Poisson regressions with random effects and receiver operator characteristic (ROC) curves to identify mobility characteristics most strongly associated with repeat IIT ( ≥ 28 days late for ART appointment during 6-month trial period) and to identify associated baseline characteristics. Of 1,119 men, 454 (41%) experienced repeat IIT; 314 (28%) took ≥ 3-night trips during the 6-month trial period. Trips ≥ 30 nights (aIRR 1.51, 95%CI 1.14–1.99, AUC 0.648) and lasting longer than expected (aIRR 1.50, 95%CI 1.15–1.96, AUC 0.653) best predicted repeat IIT (specificity 90%). No sociodemographic or pre-trial mobility variables were independently associated with high-risk mobility during the trial period. Mobility is a key risk factor for IIT among men in Malawi, and we found “high-risk mobility” to be trips ≥ 30 nights and/or that lasted longer than expected. We were unable to predict which men would experience high-risk mobility.
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,590
OpenAlex ID: W7233588804
FWCI:
Cites: 27
Cited by:
Related to: